Real-world therapeutic strategies and survival outcomes in advanced HER2-mutant non-small cell lung cancer
This study highlights the clinical features and outcomes of advanced HER2 -mutant NSCLC in Taiwan. PC + ICI may be more effective than other regimens as first-line therapy. The prognostic impact of HER2 exon 20 insertion mutations warrants further investigation.
Authors
- Yung‐Hung Luo (ORCID: https://orcid.org/0000-0002-4194-162X)
- Tsung-Ying Yang (ORCID: https://orcid.org/0000-0001-5875-3011)
- Pei-Ya Liao
- Yi‐Chen Yeh (ORCID: https://orcid.org/0000-0002-6442-4967)
- Ruei-Lin Sun (ORCID: https://orcid.org/0009-0004-7246-555X)
- Ying-Ting Liao
- Chia-I Shen
- Chi‐Lu Chiang (ORCID: https://orcid.org/0000-0003-1093-0669)
- Jeng‐Sen Tseng (ORCID: https://orcid.org/0000-0003-2341-4495)
- Kuo-Hsuan Hsu (ORCID: https://orcid.org/0000-0002-8187-904X)
- Yen-Hsiang Huang (ORCID: https://orcid.org/0000-0002-0465-5800)
- Yen-Han Tseng (ORCID: https://orcid.org/0000-0002-7504-0678)
- Hsu-Ching Huang
- Yuh-Min Chen
Institutions
- National Yang Ming Chiao Tung University (TW)
- National Chung Hsing University (TW)
- Taipei Veterans General Hospital (TW)
- Taichung Veterans General Hospital (TW)
Publication Details
- Journal
- Journal of the Chinese Medical Association
- Published
- 2025-01-27
- DOI
- https://doi.org/10.1097/jcma.0000000000001212
- Citations
- 5
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 7.59